Document Detail

The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - a review.
MedLine Citation:
PMID:  21870142     Owner:  NLM     Status:  Publisher    
Initially described as key regulators in metabolic bone disease osteoprotegerin (OPG), receptor activator of nuclear factor kappa B (RANK) and RANK ligand (RANKL) have also been discriminated as regulators in immunologic function. Cardiovascular diseases (CVD) develop over many years in life and are often triggered by inflammatory processes within the vessel wall that lead to vascular remodeling. Recently some study groups have described OPG as a prognostic parameter for mortality and morbidity in cardiovascular patients.
Daniela-Eugenia Malliga; Doris Wagner; Astrid Fahrleitner-Pammer
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-9-2
Journal Detail:
Title:  Wiener medizinische Wochenschrift (1946)     Volume:  -     ISSN:  1563-258X     ISO Abbreviation:  -     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-8-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8708475     Medline TA:  Wien Med Wochenschr     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Division of Cardiac Surgery, Department of Surgery, Medical University of Graz, Graz, Austria.
Vernacular Title:
Osteoprotegerin (OPG) und Receptor Activator for Nuclear Factor kappaB Ligand (RANKL) als Risikofaktoren für Entstehung und Schweregrad einer Koronaren Herzerkrankung - ein Review.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Guide values for heart rate and blood pressure with reference to 20, 40, 60 und 80% of maximum exert...
Next Document:  Acute renal artery aneurysm rupture - a rare differential diagnosis of acute appendicitis.